Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lexaria Bioscience (LEXX) Enterprise Value (2016 - 2025)

Lexaria Bioscience's Enterprise Value history spans 11 years, with the latest figure at -$4.8 million for Q4 2025.

  • For Q4 2025, Enterprise Value rose 43.35% year-over-year to -$4.8 million; the TTM value through Nov 2025 reached -$4.8 million, up 43.35%, while the annual FY2025 figure was -$2.2 million, 68.11% up from the prior year.
  • Enterprise Value for Q4 2025 was -$4.8 million at Lexaria Bioscience, down from -$2.2 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$1.8 million in Q3 2023 and bottomed at -$12.0 million in Q3 2021.
  • The 5-year median for Enterprise Value is -$6.7 million (2022), against an average of -$6.5 million.
  • The largest annual shift saw Enterprise Value crashed 1559.16% in 2021 before it surged 71.56% in 2023.
  • A 5-year view of Enterprise Value shows it stood at -$10.4 million in 2021, then surged by 50.59% to -$5.1 million in 2022, then soared by 53.31% to -$2.4 million in 2023, then crashed by 254.64% to -$8.5 million in 2024, then skyrocketed by 43.35% to -$4.8 million in 2025.
  • Per Business Quant, the three most recent readings for LEXX's Enterprise Value are -$4.8 million (Q4 2025), -$2.2 million (Q3 2025), and -$5.0 million (Q2 2025).